The FDA approved a tyrosine kinase inhibitor for certain patients with thyroid cancer. The U.S. Food and Drug Administration (FDA) approved cabozantinib (Cabometyx) for adult and pediatric patients 12 years of age and older...
The FDA has expanded the approval of a molecularly targeted therapeutic to treat certain pediatric and adult patients with medullary thyroid cancer. The U.S. Food and Drug Administration has approved pralsetinib (Gavreto) to treat certain adult and pediatric patients age...
A study finds that incidence of thyroid cancer rose by 169% between 1990 and 2017, and more news of the week from Cancer Today.
Thyroid cancer survivors – especially those diagnosed before age 40 – have elevated risk for several aging-related diseases.
The FDA's approval of a targeted therapeutic called lenvatinib provides another option for patients certain forms of thyroid cancer.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now